BNGO — BioNano Genomics Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMid CapMomentum Trap
- $1.04bn
- $861.09m
- $17.98m
- 15
- 10
- 71
- 22
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.67 | ||
| Price to Tang. Book | 5.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 44.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.97% | ||
| Return on Equity | -33.56% | ||
| Operating Margin | -478% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.51 | 12 | 10.13 | 8.5 | 17.98 | 26.41 | 47.07 | 21.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bionano Genomics, Inc. is a genomics company, which provides optical genome mapping (OGM) for genome analysis. The Company offers diagnostic services to physicians specializing in medical management for individuals with genetic conditions, such as pediatric neurodevelopmental disorders, including autism spectrum disorders. It markets and sell the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation. Its Lineagen business provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, it offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
Directors
- David Barker NEC (79)
- R. Erik Holmlin PRE (53)
- Christopher Stewart CFO (51)
- Mark Oldakowski COO (47)
- Alka Chaubey OTH (48)
- Jason Priar OTH
- Vincent Wong DRC
- Yvonne Linney IND (59)
- Albert Luderer IND (72)
- Hannah Mamuszka IND (44)
- Christopher Twomey IND (61)
- Kristiina Vuori IND (53)
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2022
- Incorporated
- January 24th, 2003
- Public Since
- August 1st, 2018
- No. of Shareholders
- 108
- No. of Employees
- 299
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 290,139,940
- Address
- 9640 TOWNE CENTRE DRIVE, SAN DIEGO, 92121
- Web
- https://bionanogenomics.com/
- Phone
- +1 8588887600
- Contact
- Amy Conrad
- Auditors
- BDO USA, LLP
Upcoming Events for BNGO
Similar to BNGO
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
Allied Healthcare Products
NASDAQ Capital Market
FAQ
What is the BioNano Genomics share price?
As of Today at 19:03 UTC, shares in BioNano Genomics are trading at $3.60. This share price information is delayed by 15 minutes.
How has the BioNano Genomics share price performed this year?
Shares in BioNano Genomics last closed at $3.60 and the price had moved by -39.6% over the past 365 days. In terms of relative price strength the BioNano Genomics share price has underperformed the S&P500 Index by -36.95% over the past year.
What are the analyst and broker recommendations for BioNano Genomics?
The overall consensus recommendation for BioNano Genomics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the BioNano Genomics dividend yield?
BioNano Genomics does not currently pay a dividend.
Does BioNano Genomics pay a dividend?
BioNano Genomics does not currently pay a dividend.
When does BioNano Genomics next pay dividends?
BioNano Genomics does not currently pay a dividend.
How do I buy BioNano Genomics shares?
To buy shares in BioNano Genomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of BioNano Genomics?
As of the previous close price of $3.60, shares in BioNano Genomics had a market capitalisation of $1.04bn.
Where are BioNano Genomics shares listed?
Here are the trading details for BioNano Genomics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BNGO
What kind of share is BioNano Genomics?
Based on an overall assessment of its quality, value and momentum BioNano Genomics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a BioNano Genomics share price forecast for 2022?
The analyst consensus target price for shares in BioNano Genomics is $8.67. That is 140.83% above the last closing price of $3.60.
Analysts covering BioNano Genomics currently have a consensus Earnings Per Share (EPS) forecast of -$0.44 for the next financial year.
What is the trend in the BioNano Genomics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioNano Genomics. Over the past six months, its share price has outperformed the S&P500 Index by +69.05%.
As of the last closing price of $3.60, shares in BioNano Genomics were trading +44.94% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the BioNano Genomics PE Ratio?
The BioNano Genomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of BioNano Genomics?
BioNano Genomics' management team is headed by:
- David Barker - NEC
- R. Erik Holmlin - PRE
- Christopher Stewart - CFO
- Mark Oldakowski - COO
- Alka Chaubey - OTH
- Jason Priar - OTH
- Vincent Wong - DRC
- Yvonne Linney - IND
- Albert Luderer - IND
- Hannah Mamuszka - IND
- Christopher Twomey - IND
- Kristiina Vuori - IND